Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date29 Apr 2019 |
|
Mechanism5-HT3 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date25 Jul 2003 |
|
Mechanism5-HT1A receptor agonists [+3] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date15 Nov 2002 |
健康受试者在空腹条件下口服富马酸二甲酯肠溶胶囊120 mg受试制剂和参比制剂的生物等效性试验
[Translation] Bioequivalence test of test preparation and reference preparation after oral administration of dimethyl fumarate enteric-coated capsules 120 mg to healthy subjects under fasting conditions
评价空腹条件下富马酸二甲酯肠溶胶囊120 mg受试制剂与参比制剂的生物等效性以及安全性
[Translation] To evaluate the bioequivalence and safety of the test preparation and reference preparation of dimethyl fumarate enteric-coated capsules 120 mg under fasting conditions
盐酸帕洛诺司琼口颊膜的安全性、耐受性和相对生物利用度的Ⅰ期试验
[Translation] Phase I trial on the safety, tolerability and relative bioavailability of palonosetron hydrochloride buccal membrane
评估健康受试者在空腹条件下服用0.5 mg盐酸帕洛诺司琼口颊膜的相对生物利用度、安全性和耐受性。
[Translation] To evaluate the relative bioavailability, safety, and tolerability of 0.5 mg palonosetron hydrochloride bucally administered to healthy subjects under fasting conditions.
健康受试者在餐后条件下口服富马酸二甲酯肠溶胶囊120 mg受试制剂和参比制剂的生物等效性试验
[Translation] Bioequivalence study of test preparation and reference preparation of dimethyl fumarate enteric-coated capsules 120 mg orally administered to healthy subjects under postprandial conditions
评价富马酸二甲酯肠溶胶囊120 mg受试制剂与参比制剂的生物等效性以及安全性
[Translation] Evaluation of the bioequivalence and safety of dimethyl fumarate enteric-coated capsules 120 mg between the test preparation and the reference preparation
100 Clinical Results associated with Xiamen LP Pharmaceutical Co., Ltd
0 Patents (Medical) associated with Xiamen LP Pharmaceutical Co., Ltd
100 Deals associated with Xiamen LP Pharmaceutical Co., Ltd
100 Translational Medicine associated with Xiamen LP Pharmaceutical Co., Ltd